Cargando…
Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) now has two licensed treatments available. Pirfenidone was the first drug to be licensed and approved for use, followed by nintedanib. We set out our real world experience with these agents in terms of their adverse events profile outside the restrictions of a cli...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039481/ https://www.ncbi.nlm.nih.gov/pubmed/27598213 http://dx.doi.org/10.3390/jcm5090078 |
_version_ | 1782456064883556352 |
---|---|
author | Hughes, Gareth Toellner, Hannah Morris, Helen Leonard, Colm Chaudhuri, Nazia |
author_facet | Hughes, Gareth Toellner, Hannah Morris, Helen Leonard, Colm Chaudhuri, Nazia |
author_sort | Hughes, Gareth |
collection | PubMed |
description | Idiopathic Pulmonary Fibrosis (IPF) now has two licensed treatments available. Pirfenidone was the first drug to be licensed and approved for use, followed by nintedanib. We set out our real world experience with these agents in terms of their adverse events profile outside the restrictions of a clinical trial. We have demonstrated in the real world setting, that side effects are common and predominantly gastrointestinal with both therapies. Our study shows that the side effects can be effectively managed in the majority of patients with an acceptable discontinuation rate similar to that seen in the clinical trials. These findings are compelling despite the fact that the patients in our study are older, have severer disease as depicted by baseline lung function and more co-morbidities. Our data provides ongoing evidence of the safety and tolerability of both pirfenidone and nintedanib in patients who would not have met the rigorous criteria to be included in a clinical trial. Both these agents are effective in the management of IPF and slow the progression of this debilitating life limiting condition. |
format | Online Article Text |
id | pubmed-5039481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-50394812016-10-04 Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis Hughes, Gareth Toellner, Hannah Morris, Helen Leonard, Colm Chaudhuri, Nazia J Clin Med Review Idiopathic Pulmonary Fibrosis (IPF) now has two licensed treatments available. Pirfenidone was the first drug to be licensed and approved for use, followed by nintedanib. We set out our real world experience with these agents in terms of their adverse events profile outside the restrictions of a clinical trial. We have demonstrated in the real world setting, that side effects are common and predominantly gastrointestinal with both therapies. Our study shows that the side effects can be effectively managed in the majority of patients with an acceptable discontinuation rate similar to that seen in the clinical trials. These findings are compelling despite the fact that the patients in our study are older, have severer disease as depicted by baseline lung function and more co-morbidities. Our data provides ongoing evidence of the safety and tolerability of both pirfenidone and nintedanib in patients who would not have met the rigorous criteria to be included in a clinical trial. Both these agents are effective in the management of IPF and slow the progression of this debilitating life limiting condition. MDPI 2016-09-02 /pmc/articles/PMC5039481/ /pubmed/27598213 http://dx.doi.org/10.3390/jcm5090078 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hughes, Gareth Toellner, Hannah Morris, Helen Leonard, Colm Chaudhuri, Nazia Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis |
title | Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis |
title_full | Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis |
title_fullStr | Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis |
title_full_unstemmed | Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis |
title_short | Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis |
title_sort | real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039481/ https://www.ncbi.nlm.nih.gov/pubmed/27598213 http://dx.doi.org/10.3390/jcm5090078 |
work_keys_str_mv | AT hughesgareth realworldexperiencespirfenidoneandnintedanibareeffectiveandwelltoleratedtreatmentsforidiopathicpulmonaryfibrosis AT toellnerhannah realworldexperiencespirfenidoneandnintedanibareeffectiveandwelltoleratedtreatmentsforidiopathicpulmonaryfibrosis AT morrishelen realworldexperiencespirfenidoneandnintedanibareeffectiveandwelltoleratedtreatmentsforidiopathicpulmonaryfibrosis AT leonardcolm realworldexperiencespirfenidoneandnintedanibareeffectiveandwelltoleratedtreatmentsforidiopathicpulmonaryfibrosis AT chaudhurinazia realworldexperiencespirfenidoneandnintedanibareeffectiveandwelltoleratedtreatmentsforidiopathicpulmonaryfibrosis |